Real-World Outcomes of Glofitamab therapy in CAR-T naïve Patients with Relapsed/Refractory Large B-cell lymphoma
Authors:
- Liudmila FedorovaLFLiudmila Fedorova
- Natalia MikhailovaNMNatalia Mikhailova
- Kirill LepikKLKirill Lepik
- Vladislav MarkelovVMVladislav Markelov
- Andrey ChekalovACAndrey Chekalov
- Olesya SmykovaOSOlesya Smykova
- Gayane TumyanGTGayane Tumyan
- Anastasia SemenovaASAnastasia Semenova
- Arman ArakelyanAAArman Arakelyan
- Lev ButaevLBLev Butaev
- Yuliia OleinikYOYuliia Oleinik
- Vadim PtushkinVPVadim Ptushkin
Open Access
- 6 July 2026
- journal article
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (3)
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working partyBone Marrow Transplantation, 2025
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialThe Lancet, 2024
- Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell LymphomaTransplantation and Cellular Therapy, 2024
- Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapyHemaSphere, 2024
- New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO groupHemaSphere, 2024
- Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world dataHematological Oncology, 2023
- Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gapBlood Reviews, 2021
- Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in SwedenBlood Cancer Journal, 2021
- Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trialAnnals of Oncology, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019